Business
Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that its in-house discovered CLDN18.2 ADC, ATG-022,was granted a Breakthrough Therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment o
About this update from Antengene Corporation Limited
[{"type":"text","content":"SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that its in-house discovered CLDN18.2 ADC, ATG-022,was granted a Breakthrough Therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of CLDN18.2-positive, HER-2 negative unresectable or metastatic gastric or gastroesophageal junction (GC/GEJ) in patients who have received at least two prior lines of therapy.","length":739,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Antengene Corporation Limited)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Antengene Corporation Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":170,"url":"https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5j2U0HrCj8zISzT4Iv1xLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583","width":400,"height":170}},"href":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"To provide further details on the latest clinical data of ATG-022, Antengene's management team will host a conference call on August 20, 2025 (Wednesday), from 9:00 am to 10:00 am (Beijing Time). ","length":199,"tagName":"p"},{"type":"text","content":"Ways to Participate: ","length":20,"tagName":"p"},{"type":"text","content":"1. Webcast: https://s.comein.cn/5hgdc8k2","length":50,"tagName":"p"},{"type":"text","content":"2. Conference Call: (Dial-in From China)Mainland of China: +86-4001510269 Global: +86-01021377168 (Dial-in From Overseas)Hong Kong, China: +852-51089680 Hong Kong, China: +852-800931266 Taiwan, China: +886-277083288 Global: +86-01021377168 United States: +1-2087016888 Access Code: 303021","length":303,"tagName":"p"},{"type":"text","content":"Management Participants:","length":24,"tagName":"p"},{"type":"text","content":"Dr. Jay MeiFounder, C...